Weill Cornell Leukemia Program

Call Directions Website

Weill Cornell Leukemia Program Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Weill Cornell Leukemia Program, Hospital, 520 East 70th Street, Starr Pavilion, 3rd Floor, New York, NY.

The Leukemia Program provides:

--A multidisciplinary team with specialists in infectious diseases, geriatrics, gastroenterology, cardiology, nephrology, neurology, pulmonary and critical care medicine, psychiatry, social work, nutrition and others

--Emphasis on highly personalized, individual care

--Close collaboration with comprehensive bone marrow and stem cell transplantation program

--Access to cutting edge clinical trials involving newly developed drugs, biological therapies and antibodies

--Specialized in-patient and out-patient units with highly trained staff and ancillary professionals experienced with the specific needs of these patients

--Extensive collaborations with world-renowned translational scientists, specific expertise in leukemia stem cells, genomics, epigenetics

--Specialized focus on development of clinical trials targeting leukemia stem cells, both at the time of diagnosis as well as trying to target and eradicate left-over leukemia stem cells in patients already in remission. The Leukemia Fighters Fund accepts charitable donations which are completely and specifically for leukemia research at Weill Cornell, has already provided funds for new recruits, novel treatment protocols, equipment and other critical needs

Watch Dr. Gail Roboz discuss the   that she led on an all-oral treatment for acute myeloid   (AML). This combination the...
10/21/2026

Watch Dr. Gail Roboz discuss the that she led on an all-oral treatment for acute myeloid (AML). This combination therapy was U.S. Food and Drug Administration approved for newly-diagnosed older patients & those who cannot tolerate intensive :

Dr. Gail Roboz: All-Oral Regimen for AML Provides New Treatment Pathway

10/07/2026

Certain age-related blood mutations, known as clonal hematopoiesis, may be linked to increased risk of , heart disease, stroke & chronic inflammation. Dr. Pinkal Desai joined Weill Cornell Medicine to explain: https://bit.ly/4nIJbcl

Podcast Episode · CancerCast · May 22 · 32m

08/07/2026

At , Dr. Gail Roboz chaired the session on optimizing treatment for patients with a certain subset of acute myeloid (AML): https://bit.ly/4wq0iDn

08/06/2026

Dr. Pinkal Desai was part of a study using artificial intelligence ( ) to map bone marrow architecture to provide a more accurate view of . Learn more:

Mapping bone marrow architecture using an artificial intelligence (AI)-derived score provided a more accurate view of disease state in myelodysplastic neoplasms (MDS) than molecular or blast-based ass...

08/03/2026

Results from a led by Dr. Gail Roboz demonstrated that an all-oral regimen for newly diagnosed acute myeloid (AML) offers an alternative for patients ineligible for intensive : https://bit.ly/4yOhx2H

07/31/2026

WATCH: Dr. Pinkal Desai spoke at an session on optimizing frontline treatment for improved outcomes in lower-risk

This lower-risk myelodysplastic syndromes symposium provided an overview of emerging data from pivotal trials and real-world evidence...

06/24/2026

FRIDAY, June 5, 2026 (HealthDay News) — An already available two-pill combo treats leukemia just as well as IV drugs, which should make cancer treatment easier

ICYMI: An all-oral treatment regimen for older adults with acute myeloid   ( ) received U.S. Food and Drug Administratio...
06/22/2026

ICYMI: An all-oral treatment regimen for older adults with acute myeloid ( ) received U.S. Food and Drug Administration approval based on led by Dr. Gail Roboz recently published in The New England Journal of Medicine. Get the breakdown via The ASCO Post

An all-oral treatment regimen led to complete responses in almost half of all patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, according to fi...

  led by Dr. Gail Roboz published in The New England Journal of Medicine showed that an oral treatment combination was e...
06/15/2026

led by Dr. Gail Roboz published in The New England Journal of Medicine showed that an oral treatment combination was effective for older adults with acute myeloid ( ) leading to U.S. Food and Drug Administration approval: https://bit.ly/49XHQJ9 (cc: U.S. News and World Report)

US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.

Congratulations to Dr. Pinkal Desai for being awarded the Weill Cornell Medicine Jeanne and Herbert Siegel Faculty Devel...
06/05/2026

Congratulations to Dr. Pinkal Desai for being awarded the Weill Cornell Medicine Jeanne and Herbert Siegel Faculty Development Award for her exemplary clinical and research contributions! https://bit.ly/42EO3FT

Address

520 East 70th Street, Starr Pavilion, 3rd Floor
New York, NY
10021

Alerts

Be the first to know and let us send you an email when Weill Cornell Leukemia Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share

Category